Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

In Vitro Models of Liver and Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02436564
Recruitment Status : Unknown
Verified July 2016 by Dr. Kourosh Saeb-Parsy, Cambridge University Hospitals NHS Foundation Trust.
Recruitment status was:  Recruiting
First Posted : May 7, 2015
Last Update Posted : July 14, 2016
Sponsor:
Collaborators:
The Gurdon Institute
Ann McLaren Laboratory of Regenerative Medicine
Information provided by (Responsible Party):
Dr. Kourosh Saeb-Parsy, Cambridge University Hospitals NHS Foundation Trust

Brief Summary:

The primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue. The secondary objective is to study the genetic and cellular biology of cancer of the liver, biliary tract and the pancreas. As well the investigators hope to compare molecular and cellular biology of cancer cells with normal cells as well as potentially test the efficacy of current and future anti-cancer therapies.

Samples will be collected from tissue that has been resected as part of the treatment for a patient diagnosed with liver, bile duct or pancreas cancer.


Condition or disease Intervention/treatment
Cholangiocarcinoma Hepatocellular Carcinoma Pancreatic Neoplasm Genetic: Organoid in vitro culture

Layout table for study information
Study Type : Observational
Estimated Enrollment : 75 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Study Designed to Develop in Vitro Models of Liver, Biliary and Pancreatic Cancer for the Investigation of Tumour Biology and Potential Therapies
Study Start Date : July 2015
Estimated Primary Completion Date : September 2018

Resource links provided by the National Library of Medicine



Intervention Details:
  • Genetic: Organoid in vitro culture
    Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.


Primary Outcome Measures :
  1. Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Proportion of tumour-derived organoids that are genetically identical to the source tumour. [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
fresh tissue, frozen tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who are undergoing surgical resenctions of liver, biliary or pancreas cancers that are able to give informed consent
Criteria

Inclusion Criteria:

  • All adult patients undergoing surgical resections for liver, biliary or pancreas cancers that are able to give informed consent.

Exclusion Criteria:

  • Patients aged <18 or those who are unable to give informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02436564


Contacts
Layout table for location contacts
Contact: Kourosh Saeb-Parsy, PhD, FRCS (+44 1223 7) 68456 ks10014@cam.ac.uk
Contact: Nikitas Georgakopoulos, BSc 07554003700 ng395@cam.ac.uk

Locations
Layout table for location information
United Kingdom
Addenbrooke's Hospital Recruiting
Cambridge, United Kingdom, CB2 0QQ
Contact: Andrew Bradley, PhD, FRCS    (3)36976 (7)62001    jab52@cam.ac.uk   
Sponsors and Collaborators
Cambridge University Hospitals NHS Foundation Trust
The Gurdon Institute
Ann McLaren Laboratory of Regenerative Medicine
Investigators
Layout table for investigator information
Principal Investigator: Kourosh Saeb-Parsy, PhD, FRCS Cambridge Univeristy Hospitals
Layout table for additonal information
Responsible Party: Dr. Kourosh Saeb-Parsy, University Lecturer and Consulatan Transplant Surgeon, Cambridge University Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT02436564    
Other Study ID Numbers: A093484
First Posted: May 7, 2015    Key Record Dates
Last Update Posted: July 14, 2016
Last Verified: July 2016
Keywords provided by Dr. Kourosh Saeb-Parsy, Cambridge University Hospitals NHS Foundation Trust:
pancreas
stem cells
tumours
in vitro models
organoids
cancer,
bile duct
liver
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Cholangiocarcinoma
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type